Company: MYSZ
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000990
Chunk: 290

Company: My Size, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 290
---
 that, if the voting power held by the Proxy, taking into account the proxies granted by the Naiz Acquisition Stockholders
and the Shares owned by the Proxy, represents 20% or more of the voting power of My Size’s stockholders that will vote on an item,
or the Voting Power, then the Proxy shall vote such number of Shares in excess of 19.9% of the Voting Power in the same proportion as
the Shares that are voted by My Size’s other stockholders. The Voting Agreement will terminate on the earliest to occur of (i)
such time that such Naiz Acquisition Stockholder no longer owns the Shares, (ii) the sale of all or substantially all of the assets of
My Size or the consolidation or merger of My Size with or into any other business entity pursuant to which stockholders of My Size prior
to such consolidation or merger hold less than 50% of the voting equity of the surviving or resulting entity, (iii) the liquidation,
dissolution or winding up of the business operations of My Size, and (iv) the filing or consent to filing of any bankruptcy, insolvency
or reorganization case or proceeding involving My Size or otherwise seeking any relief under any laws relating to relief from debts or
protection of debtors.

Operations
in Russia

In
addition to our Israel operations, we historically had operations in Russia through our wholly owned subsidiary, My Size LLC. To date,
mainly due to the invasion of Ukraine by Russia and the ongoing sanctions we ceased most of our efforts in Russia and expect to dissolve
the subsidiary in the near future.

Results
of Operations

The
table below provides our results of operations for the periods indicated.

    Year
    ended December 31 

    2024  
    2023 

    (dollars in thousands) 
  
    Revenues 
     8,257  
     6,996 
  
    Cost of revenues 
     (4,934) 
     (4,265)
  
    Gross profit 
     3,323  
     2,731 
  
    Research and development expenses 
    $(429) 
    $(974)
  
    Sales and marketing 
     (3,114) 
     (3,856)
  
    General and administrative 
     (3,368) 
     (3,971)
  
    Other income 
     275  
     - 
  
    Impairment